Integrin β3 and CD44 levels determine the effects of the OPN-a splicing variant on lung cancer cell growth

Oncotarget. 2016 Aug 23;7(34):55572-55584. doi: 10.18632/oncotarget.10865.

Abstract

Osteopontin (OPN), a phosphorylated glycoprotein, is frequently overexpressed in cancer. Among the three OPN isoforms, OPN-a is the most highly expressed in lung cancer cell lines and lung tumors. Overexpression of OPN-a greatly reduced CL1-5 lung adenocarcinoma cell growth, but had no effect on growth in A549 lung adenocarcinoma cells. Examination of the expression of integrins and CD44, which are possible OPN-a receptors, revealed that differences in integrin β3 levels might explain this discrepancy between CL1-5 and A549 cells. When integrin β3 was ectopically expressed in A549 cells, OPN-a inhibited their growth, whereas OPN-a increased cell growth following integrin β3 knockdown in CL1-5 cells. This OPN-a-induced increase in growth appeared to result from activation of the CD44/NFκB pathway. Our results demonstrated that OPN-a inhibits growth of cells with high integrin β3 levels and increases growth via activation of the CD44/NFκB pathway in cells with low integrin β3 levels. Thus, OPN-a, integrin β3, and CD44 interact to affect lung cancer cell growth, and this study may aid in the development of cancer treatment strategies involving these molecules.

Keywords: CD44; NF-kB; OPN-a; integrin β3.

MeSH terms

  • Cell Line, Tumor
  • Cell Proliferation
  • Humans
  • Hyaluronan Receptors / analysis
  • Hyaluronan Receptors / physiology*
  • Integrin beta3 / analysis
  • Integrin beta3 / physiology*
  • Lung Neoplasms / pathology*
  • NF-kappa B / physiology
  • Osteopontin / analysis
  • Osteopontin / physiology*
  • RNA Splicing

Substances

  • CD44 protein, human
  • Hyaluronan Receptors
  • ITGB3 protein, human
  • Integrin beta3
  • NF-kappa B
  • SPP1 protein, human
  • Osteopontin